Over the past four decades, we have seen a significant increase in people across Europe being affected by hepatitis B and C; both serious, asymptomatic, infectious diseases that kill around 120,000 people in Europe every year.1 In response to this, a large body of work has been produced over the past three years, giving information and recommendations on how to address the burden of the disease.